Fermentalg Valuation
Is 1F6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1F6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1F6 (€0.32) is trading below our estimate of fair value (€1.06)
Significantly Below Fair Value: 1F6 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1F6?
Key metric: As 1F6 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 1F6's PS Ratio? | |
|---|---|
| PS Ratio | 3.9x |
| Sales | €8.04m |
| Market Cap | €31.22m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3x |
| Enterprise Value/EBITDA | -2.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 1F6's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
BNN BRAIN Biotech | 1.3x | 8.5% | €70.8m |
NTG Nabaltec | 0.6x | 5.1% | €122.3m |
2HRA H&R GmbH KGaA | 0.1x | 3.0% | €128.4m |
BIG1 Bio-Gate | 0.8x | 16.3% | €6.3m |
1F6 Fermentalg | 3.9x | 38.0% | €31.2m |
Price-To-Sales vs Peers: 1F6 is expensive based on its Price-To-Sales Ratio (3.9x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does 1F6's PS Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Sales vs Industry: 1F6 is expensive based on its Price-To-Sales Ratio (3.9x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 1F6's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.9x |
| Fair PS Ratio | 0.7x |
Price-To-Sales vs Fair Ratio: 1F6 is expensive based on its Price-To-Sales Ratio (3.9x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.32 | €0.80 +149.2% | 25.0% | €1.00 | €0.60 | n/a | 2 |
| Apr ’24 | €1.12 | €3.25 +191.0% | 13.8% | €3.70 | €2.80 | €0.66 | 2 |
| Mar ’24 | €1.51 | €3.40 +125.2% | 8.8% | €3.70 | €3.10 | €0.58 | 2 |
| Feb ’24 | €1.50 | €3.40 +126.4% | 8.8% | €3.70 | €3.10 | €0.62 | 2 |
| Jan ’24 | €1.50 | €3.40 +126.2% | 8.8% | €3.70 | €3.10 | €0.29 | 2 |
| Dec ’23 | €1.62 | €3.40 +109.6% | 8.8% | €3.70 | €3.10 | €0.25 | 2 |
| Nov ’23 | €1.85 | €3.40 +83.8% | 8.8% | €3.70 | €3.10 | €0.32 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Stanmore Resources
AU$2.8b
Engages in the exploration, development, production, and sale of metallurgical coal in Australia.
S0D
AU$1.88
7D
0.5%
1Y
-16.8%
Tokuyama
JP¥197.6b
Produces and sells various chemical products in Japan.
TBT
JP¥16.70
7D
5.0%
1Y
16.0%
Mitsubishi Chemical Group
JP¥1.2t
Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.
M3C
JP¥5.27
7D
2.9%
1Y
-8.1%